Acne Medication Market Size and Share

Plastic Optic Fiber Market Report Thumbnail

Acne Medication Market by Therapeutic Class (Retinoids, Antibiotics, Benzoyl Peroxide, Salicylic Acid, and Others), Formulation (Topical Medications and Oral Medications), Type (Prescription Medicines and Over-The-Counter Medicines), Acne Type (Non-Inflammatory Acne and Inflammatory Acne), and Distribution Channel (Retail Stores, E-Commerce, and Pharmacies & Drug Stores) – Global Opportunity Analysis and Industry Forecast, 2023-2030

Download PDF

Speak to Our Analyst

Market Definition

The global Acne Medication Market was valued at USD 10.08 billion in 2021 and is predicted to reach USD 14.26 billion by 2030, with a CAGR of 3.02% from 2022 to 2030. Acne is a type of skin condition in which the hair follicles become plugged with dead skin cells and oil.

Two varieties of acne are non-inflammatory and inflammatory, with the inflammatory taking longer to cure and potentially leaving permanent consequences on the skin. It develops when the openings of hair follicles become clogged and blocked with oil or dead skin cells.

This condition further causes blackheads, whiteheads, or pimples. Acne is most common among teenagers and generally affects skin with a relatively high number of sweat glands such as the back, upper part of the chest, and face. Drugs involved in the treatment of acne are referred to as acne medication. Such type of medication comprises several prescription and over-the-counter medicines such as retinoids, benzoyl peroxide, antibiotics, isotretinoin, salicylic acid, and oral contraceptives.

In addition, acne medication includes medicated creams, gels, and ointments that are applied directly to infected parts of the body to reduce oil production and swelling. In the case of moderate to severe acne, oral medication is preferred for treatment.

Adoption of Acne Medication, Owing to Unhealthy Food Habits and Sedentary Lifestyles

Acne is mainly associated with a diet rich in fats, calories, and refined carbohydrates. It includes food items, such as burgers, hot dogs, potato fries, sodas, nuggets, and milkshakes, which support and may lead to an increased risk of acne.

According to the National Library of Medicine, around 5,000 Chinese young adults and teenagers found that high-fat diets were linked with a 43% higher risk of developing acne. Diets comprising large amounts of omega-6 fatty acids have been associated with increased levels of inflammation and acne.

Furthermore, inactivity or sedentary lifestyles negatively affect the skin with extra fat leading to an increased body mass index, which contributes to a number of health issues. This further leads to issues associated with the hormones, affecting the skin. Thus, unhealthy food habits and the rise in sedentary lifestyles fuel the acne treatment market share.

Occurrence of Acne Vulgaris Condition in Teenagers and Adults

Acne vulgaris is one of the most common skin conditions affecting adolescents & adults across the globe. Teenagers are most likely to get acne, owing to their diet, genetics, and hormones during puberty. For instance, acne vulgaris is estimated to affect over 50 million people in the U.S. while about 85% of teenagers are affected by acne; however, it can occur in any age group with many cases persisting into adulthood.

Furthermore, according to the U.S. National Institutes of Health, around 80% of people aged between 11 to 30 experience acne at some point in their lives. On the contrary, adults, particularly women are more likely to develop acne from hormonal fluctuations during menstruation as well as pregnancy. Hence, the occurrence of acne vulgaris condition in teenagers & adults propels the acne medication market growth.

Side Effects of Acne Medications and Substitute Acne Treatment Options

Various acne medications have different side effects that vary depending on the consumption method user chooses, as well as the strength of the medication. For instance, topical acne drugs have the most common side effects of skin irritation and dryness. On the other hand, antibiotics may result in an upset stomach or make the user lightheaded and dizzy.

In addition, side effects of oral contraceptives include high blood pressure and increased risk of blood clots. Moreover, this medication may have the side effect of suicidal thoughts and increased risk of depression, along with the effect on cholesterol levels and liver function. Such side effects of acne medications hamper the growth of the acne drug industry.

The Emergence of Effective Acne Medications with Minor Side Effects

Leading market players are significantly making efforts to introduce effective acne medications with minor side effects. For instance, in February 2020, Sun Pharmaceutical Industries Ltd., an Indian multinational pharmaceutical company announced that one of its subsidiaries has launched ABSORICA LD (isotretinoin) capsules in the U.S. for the management of severe recalcitrant nodular acne in patients aged 12 years and older. Development as well as the proliferation of such acne medication products are anticipated to create lucrative growth opportunities for the acne treatment market.

North America Holds a Major Share of the Acne Drug Market

North America leads in the market, owing to factors such as unhealthy lifestyles including a diet of the urban population that leads to the prevalence of acne in this region. According to the American Academy of Dermatology (AAD), around 50 million people suffered from acne in the U.S. in 2021.

Moreover, the presence of major key players such as Bausch Health Companies Inc., Mylan N.V., Pfizer Inc, and Johnson & Johnson further boosts the acne medication market growth in this region. For instance, in April 2020, Procter & Gamble-owned, Olay launched a new range of retinol products to target busy millennials. It consists of three products including serum, night cream, and eye cream, all of these products aim to treat acne-related problems. In addition, the United States Food and Drug Administration (FDA) is approving a number of acne treatment medicines with a number of ingredients.

For instance, in July 2021, Sol-Gel Technologies, a clinical-stage pharmaceutical company created a single-application acne treatment cream, combining two generally used ingredients: benzoyl peroxide and tretinoin. The FDA has approved tretinoin and benzoyl peroxide cream for treating acne vulgaris in individuals 9 years and older.

Europe is Expected to Show a Steady Rise in the Acne Medication Market

The rise in awareness and easy accessibility of acne medication by the common public, owing to the well-established healthcare infrastructure in this region propels the acne medication market growth. Moreover, advancements in acne medication and rigorous R&D activities by companies in Europe such as Almirall SA, Galderma SA, and GlaxoSmithKline Plc (GSK) further boost the market growth in this region. For instance, in January 2021, GlaxoSmithKline entered into a research collaboration with Eligo Bioscience. Under this strategic collaboration, GlaxoSmithKline aimed for advanced research and development of microbiome gene therapy of Eligo Bioscience called Eligobiotics for acne treatment.

Competitive Landscape

The acne medication industry comprises various market players such as Almirall SA., Bausch Health Companies Inc., Galderma S.A, Mayne Pharma Group Limited, GlaxoSmithKline Plc (GSK), Mylan N.V., Pfizer Inc., Johnson & Johnson, Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd. These market players have completed acquisitions and launched numerous products across various regions to maintain their dominance in the acne medication market.

For instance, in January 2022, Galderma S.A announced the acquisition of ALASTIN Skincare Inc. This acquisition allowed Galderma to expand its product portfolio and global market presence. Moreover, in June 2021, Almirall SA. received approval from the US Food and Drug Administration (FDA) to produce an oral antibiotic called Seysara. This approval allowed Almirall to sell Seysara in the US market to be used for treating moderate to severe acne.

Acne Medication Market Key Segments

By Therapeutic Class

Retinoids
- Topical & Combination Retinoids
- Oral Retinoids (Isotretinoin)
Antibiotics
- Topical & Combination Antibiotics
- Oral Antibiotics
Benzoyl Peroxide
Salicylic Acid
Others

By Formulation

Topical Medications
Oral Medications

By Type

Prescription Medicines
Over-The-Counter Medicines

By Acne Type

Non-Inflammatory Acne
Inflammatory Acne

By Distribution Channel

Retail Stores
E-Commerce
Pharmacies & Drug Stores

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Sweden
- Rest of Europe
Asia-Pacific
- Australia
- China
- India
- Japan
- South Korea
- Indonesia
- Singapore
- Rest of Asia-Pacific
RoW
- UAE
- Brazil
- South Africa
- Israel
- KSA (Kingdom of Saudi Arabia)
- Turkey
- Others

Report Scope and Segmentation

Parameters	Details
Market Size in 2022	USD 10.08 Billion
Revenue Forecast in 2030	USD 14.26 Billion
Growth Rate	CAGR of 3.1% from 2023 to 2030
Analysis Period	2022–2030
Base Year Considered	2021
Forecast Period	2023–2030
Market Size Estimation	Billion (USD)
Growth Factors	Adoption of acne medication, owing to unhealthy food habits sedentary lifestyles Occurrence of acne vulgaris condition in teenagers & adults
Countries Covered	26
Companies Profiled	10
Market Share	Available for 10 companies
Customization Scope	Free customization (equivalent up to 80 analysts working hours) after purchase. Addition or alteration to country, regional & segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

Almirall SA
Bausch Health Companies Inc
Galderma SA
Mayne Pharma Group Limited
GlaxoSmithKline Plc (GSK)
Mylan N.V.
Pfizer Inc.
Johnson & Johnson
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.

1. INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. WHO SHOULD READ THIS REPORT

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

1.4.1 SECONDARY RESEARCH

1.4.2 DATA ANALYSIS FRAMEWORK

1.4.3 MARKET SIZE ESTIMATION

1.4.4 FORECASTING

1.4.5 PRIMARY RESEARCH AND DATA VALIDATION

2. ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

2.1. MARKET SNAPSHOT, 2022 - 2030, MILLION USD

3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. MARKET DYNAMICS

3.2.1 DRIVERS

3.2.1.1 UNHEALTHY FOOD HABITS AND RISE IN SEDENTARY LIFESTYLES

3.2.1.2 OCCURRENCE OF ACNE VULGARIS CONDITION IN TEENAGERS & ADULTS

3.2.1.3 RISING AWARENESS ABOUT THE OVERALL APPEARANCE, HEALTH, AND ATTIRE

3.2.2 RESTRAINTS

3.2.2.1 SIDE-EFFECTS RELATED WITH THE USAGE OF ACNE MEDICATIONS AND SUBSTITUTE ACNE TREATMENT OPTIONS

3.2.3 OPPORTUNITIES

3.2.3.1 EMERGENCE & DEVELOPMENT OF EFFECTIVE ACNE MEDICATIONS WITH MINOR SIDE EFFECTS

3.2.3.2 SIGNIFICANT MARKET POTENTIAL IN UNTAPPED DEVELOPING COUNTRIES

4. COVID-19 ANALYSIS

4.1. IMPACT ON MARKET SIZE

4.2. END USER TRENDS & PREFERENCES, AND BUDGET & ECONOMIC IMPACT

4.3. KEY PLAYER STRATEGIES TO TACKLE COVID-19’S INFLUENCE ON MARKET

5. MARKET SHARE ANALYSIS

5.1. MARKET SHARE ANALYSIS OF TOP ACNE MEDICATION PROVIDERS, 2022

6. GLOBAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

6.1. OVERVIEW

6.2. RETINOIDS

6.2.1 GLOBAL RETINOIDS MARKET, BY THERAPEUTIC CLASS

6.2.1.1. TOPICAL RETINOID & COMBINATION RETIONOID MARKET, BY REGION

6.2.1.2. ORAL RETINOID (ISORETINION) MARKET, BY REGION

6.2.2 RETINOIDS MARKET, BY REGION

6.3. ANTIBIOTICS

6.3.1 GLOBAL ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

6.3.1.1. TOPICAL ANTIBIOTIC & COMBINATION ANTIBIOTICS MARKET, BY REGION

6.3.1.2. ORAL ANTIBIOTIC MARKET, BY REGION

6.3.2 ANTIBIOTICS MARKET, BY REGION

6.4. SALICYLIC ACID

6.4.1 SALICYLIC ACID MARKET, BY REGION

6.5. BENZOYL PEROXIDE

6.5.1 BENZOYL PEROXIDE MARKET, BY REGION

6.6. OTHERS

6.6.1 GLOBAL OTHERS MARKET, BY THERAPEUTIC CLASS

6.6.1.1. OTHER TOPICALS (AZELAIC ACID) MARKET, BY REGION

6.6.1.2. OTHERS OTC MARKET, BY REGION

6.6.2 OTHERS MARKET, BY REGION

7. GLOBAL ACNE MEDICATION MARKET, BY FORMULATION

7.1. OVERVIEW

7.2. TOPICAL MEDICATIONS

7.2.1 TOPICAL MEDICATIONS MARKET, BY REGION

7.3. ORAL MEDICATIONS

7.3.1 ORAL MEDICATIONS MARKET, BY REGION

8. GLOBAL ACNE MEDICATION MARKET, BY TYPE

8.1. OVERVIEW

8.2. PRESCRIPTION MEDICINES

8.2.1 PRESCRIPTION MEDICINES MARKET, BY REGION

8.3. OVER-THE-COUNTER (OTC )MEDICINES

8.3.1 OVER-THE-COUNTER (OTC )MEDICINES MARKET, BY REGION

9. GLOBAL ACNE MEDICATION MARKET, BY ACNE TYPE

9.1. OVERVIEW

9.2. INFLAMMATORY ACNE

9.2.1 INFLAMMATORY ACNE MARKET, BY REGION

9.3. NON-INFLAMMATORY ACNE

9.3.1 NON-INFLAMMATORY ACNE MARKET, BY REGION

10. GLOBAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

10.1. OVERVIEW

10.2. GROCERY SHOPS

10.2.1 GROCERY SHOPS MARKET, BY REGION

10.3. PHARMACIES & DRUG STORES

10.3.1 PHARMACIES & DRUG STORES MARKET, BY REGION

10.4. E-COMMERCE

10.4.1 E-COMMERCE MARKET, BY REGION

11. GLOBAL ACNE MEDICATION MARKET, BY REGION

11.1. OVERVIEW

11.2. NORTH AMERICA

11.2.1 NORTH AMERICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.2.1.1. NORTH AMERICA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.2.1.2. NORTH AMERICA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.2.1.3. NORTH AMERICA OTHERS MARKET, BY THERAPEUTIC CLASS

11.2.2 NORTH AMERICA ACNE MEDICATION MARKET, BY FORMULATION

11.2.3 NORTH AMERICA ACNE MEDICATION MARKET, BY TYPE

11.2.4 NORTH AMERICA ACNE MEDICATION MARKET, BY ACNE TYPE

11.2.5 NORTH AMERICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.2.6 NORTH AMERICA ACNE MEDICATION MARKET, BY COUNTRY

11.2.6.1. U.S.

11.2.6.1.1. U.S. ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.2.6.1.1.1. U.S. RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.2.6.1.1.2. U.S. ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.2.6.1.1.3. U.S. OTHERS MARKET, BY THERAPEUTIC CLASS

11.2.6.1.2. U.S. ACNE MEDICATION MARKET, BY FORMULATION

11.2.6.1.3. U.S. ACNE MEDICATION MARKET, BY TYPE

11.2.6.1.4. U.S. ACNE MEDICATION MARKET, BY ACNE TYPE

11.2.6.1.5. U.S. ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.2.6.2. CANADA

11.2.6.2.1. CANADA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.2.6.2.1.1. CANADA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.2.6.2.1.2. CANADA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.2.6.2.1.3. CANADA OTHERS MARKET, BY THERAPEUTIC CLASS

11.2.6.2.2. CANADA ACNE MEDICATION MARKET, BY FORMULATION

11.2.6.2.3. CANADA ACNE MEDICATION MARKET, BY TYPE

11.2.6.2.4. CANADA ACNE MEDICATION MARKET, BY ACNE TYPE

11.2.6.2.5. CANADA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.2.6.3. MEXICO

11.2.6.3.1. MEXICO ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.2.6.3.1.1. MEXICO RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.2.6.3.1.2. MEXICO ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.2.6.3.1.3. MEXICO OTHERS MARKET, BY THERAPEUTIC CLASS

11.2.6.3.2. MEXICO ACNE MEDICATION MARKET, BY FORMULATION

11.2.6.3.3. MEXICO ACNE MEDICATION MARKET, BY TYPE

11.2.6.3.4. MEXICO ACNE MEDICATION MARKET, BY ACNE TYPE

11.2.6.3.5. MEXICO ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3. EUROPE

11.3.1 EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.1.1. EUROPE RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.1.2. EUROPE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.1.3. EUROPE OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.2 EUROPE ACNE MEDICATION MARKET, BY FORMULATION

11.3.3 EUROPE ACNE MEDICATION MARKET, BY TYPE

11.3.4 EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.5 EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3.6 EUROPE ACNE MEDICATION MARKET, BY COUNTRY

11.3.6.1. GERMANY

11.3.6.1.1. GERMANY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.6.1.1.1. GERMANY RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.6.1.1.2. GERMANY ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.6.1.1.3. GERMANY OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.6.1.2. GERMANY ACNE MEDICATION MARKET, BY FORMULATION

11.3.6.1.3. GERMANY ACNE MEDICATION MARKET, BY TYPE

11.3.6.1.4. GERMANY ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.6.1.5. GERMANY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3.6.2. FRANCE

11.3.6.2.1. FRANCE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.6.2.1.1. FRANCE RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.6.2.1.2. FRANCE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.6.2.1.3. FRANCE OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.6.2.2. FRANCE ACNE MEDICATION MARKET, BY FORMULATION

11.3.6.2.3. FRANCE ACNE MEDICATION MARKET, BY TYPE

11.3.6.2.4. FRANCE ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.6.2.5. FRANCE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3.6.3. UK

11.3.6.3.1. UK ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.6.3.1.1. UK RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.6.3.1.2. UK ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.6.3.1.3. UK OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.6.3.2. UK ACNE MEDICATION MARKET, BY FORMULATION

11.3.6.3.3. UK ACNE MEDICATION MARKET, BY TYPE

11.3.6.3.4. UK ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.6.3.5. UK ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3.6.4. ITALY

11.3.6.4.1. ITALY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.6.4.1.1. ITALY RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.6.4.1.2. ITALY ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.6.4.1.3. ITALY OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.6.4.2. ITALY ACNE MEDICATION MARKET, BY FORMULATION

11.3.6.4.3. ITALY ACNE MEDICATION MARKET, BY TYPE

11.3.6.4.4. ITALY ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.6.4.5. ITALY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3.6.5. SPAIN

11.3.6.5.1. SPAIN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.6.5.1.1. SPAIN RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.6.5.1.2. SPAIN ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.6.5.1.3. SPAIN OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.6.5.2. SPAIN ACNE MEDICATION MARKET, BY FORMULATION

11.3.6.5.3. SPAIN ACNE MEDICATION MARKET, BY TYPE

11.3.6.5.4. SPAIN ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.6.5.5. SPAIN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.3.6.6. REST OF EUROPE

11.3.6.6.1. REST OF EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.3.6.6.1.1. REST OF EUROPE RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.3.6.6.1.2. REST OF EUROPE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.3.6.6.1.3. REST OF EUROPE OTHERS MARKET, BY THERAPEUTIC CLASS

11.3.6.6.2. REST OF EUROPE ACNE MEDICATION MARKET, BY FORMULATION

11.3.6.6.3. REST OF EUROPE ACNE MEDICATION MARKET, BY TYPE

11.3.6.6.4. REST OF EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE

11.3.6.6.5. REST OF EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4. ASIA-PACIFIC

11.4.1 ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.1.1. ASIA-PACIFIC RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.1.2. ASIA-PACIFIC ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.1.3. ASIA-PACIFIC OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.2 ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION

11.4.3 ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE

11.4.4 ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.5 ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4.6 ASIA-PACIFIC ACNE MEDICATION MARKET, BY COUNTRY

11.4.6.1. JAPAN

11.4.6.1.1. JAPAN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.6.1.1.1. JAPAN RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.6.1.1.2. JAPAN ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.6.1.1.3. JAPAN OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.6.1.2. JAPAN ACNE MEDICATION MARKET, BY FORMULATION

11.4.6.1.3. JAPAN ACNE MEDICATION MARKET, BY TYPE

11.4.6.1.4. JAPAN ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.6.1.5. JAPAN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4.6.2. CHINA

11.4.6.2.1. CHINA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.6.2.1.1. CHINA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.6.2.1.2. CHINA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.6.2.1.3. CHINA OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.6.2.2. CHINA ACNE MEDICATION MARKET, BY FORMULATION

11.4.6.2.3. CHINA ACNE MEDICATION MARKET, BY TYPE

11.4.6.2.4. CHINA ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.6.2.5. CHINA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4.6.3. INDIA

11.4.6.3.1. INDIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.6.3.1.1. INDIA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.6.3.1.2. INDIA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.6.3.1.3. INDIA OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.6.3.2. INDIA ACNE MEDICATION MARKET, BY FORMULATION

11.4.6.3.3. INDIA ACNE MEDICATION MARKET, BY TYPE

11.4.6.3.4. INDIA ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.6.3.5. INDIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4.6.4. AUSTRALIA

11.4.6.4.1. AUSTRALIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.6.4.1.1. AUSTRALIA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.6.4.1.2. AUSTRALIA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.6.4.1.3. AUSTRALIA OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.6.4.2. AUSTRALIA ACNE MEDICATION MARKET, BY FORMULATION

11.4.6.4.3. AUSTRALIA ACNE MEDICATION MARKET, BY TYPE

11.4.6.4.4. AUSTRALIA ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.6.4.5. AUSTRALIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4.6.5. SOUTH KOREA

11.4.6.5.1. SOUTH KOREA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.6.5.1.1. SOUTH KOREA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.6.5.1.2. SOUTH KOREA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.6.5.1.3. SOUTH KOREA OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.6.5.2. SOUTH KOREA ACNE MEDICATION MARKET, BY FORMULATION

11.4.6.5.3. SOUTH KOREA ACNE MEDICATION MARKET, BY TYPE

11.4.6.5.4. SOUTH KOREA ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.6.5.5. SOUTH KOREA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.4.6.6. REST OF ASIA-PACIFIC

11.4.6.6.1. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.4.6.6.1.1. REST OF ASIA-PACIFIC RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.4.6.6.1.2. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.4.6.6.1.3. REST OF ASIA-PACIFIC OTHERS MARKET, BY THERAPEUTIC CLASS

11.4.6.6.2. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION

11.4.6.6.3. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE

11.4.6.6.4. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE

11.4.6.6.5. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.5. REST OF WORLD

11.5.1 REST OF WORLD ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.5.1.1. REST OF WORLD RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.5.1.2. REST OF WORLD ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.5.1.3. REST OF WORLD OTHERS MARKET, BY THERAPEUTIC CLASS

11.5.2 REST OF WORLD ACNE MEDICATION MARKET, BY FORMULATION

11.5.3 REST OF WORLD ACNE MEDICATION MARKET, BY TYPE

11.5.4 REST OF WORLD ACNE MEDICATION MARKET, BY ACNE TYPE

11.5.5 REST OF WORLD ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.5.6 REST OF WORLD ACNE MEDICATION MARKET, BY COUNTRY

11.5.6.1. BRAZIL

11.5.6.1.1. BRAZIL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.5.6.1.1.1. BRAZIL RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.5.6.1.1.2. BRAZIL ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.5.6.1.1.3. BRAZIL OTHERS MARKET, BY THERAPEUTIC CLASS

11.5.6.1.2. BRAZIL ACNE MEDICATION MARKET, BY FORMULATION

11.5.6.1.3. BRAZIL ACNE MEDICATION MARKET, BY TYPE

11.5.6.1.4. BRAZIL ACNE MEDICATION MARKET, BY ACNE TYPE

11.5.6.1.5. BRAZIL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.5.6.2. KINGDOM OF SAUDI ARABIA (KSA)

11.5.6.2.1. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.5.6.2.1.1. KINGDOM OF SAUDI ARABIA (KSA) RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.5.6.2.1.2. KINGDOM OF SAUDI ARABIA (KSA) ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.5.6.2.1.3. KINGDOM OF SAUDI ARABIA (KSA) OTHERS MARKET, BY THERAPEUTIC CLASS

11.5.6.2.2. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY FORMULATION

11.5.6.2.3. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY TYPE

11.5.6.2.4. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY ACNE TYPE

11.5.6.2.5. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.5.6.3. SOUTH AFRICA

11.5.6.3.1. SOUTH AFRICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.5.6.3.1.1. SOUTH AFRICA RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.5.6.3.1.2. SOUTH AFRICA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.5.6.3.1.3. SOUTH AFRICA OTHERS MARKET, BY THERAPEUTIC CLASS

11.5.6.3.2. SOUTH AFRICA ACNE MEDICATION MARKET, BY FORMULATION

11.5.6.3.3. SOUTH AFRICA ACNE MEDICATION MARKET, BY TYPE

11.5.6.3.4. SOUTH AFRICA ACNE MEDICATION MARKET, BY ACNE TYPE

11.5.6.3.5. SOUTH AFRICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11.5.6.4. REMAINING COUNTRIES

11.5.6.4.1. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

11.5.6.4.1.1. REMAINING COUNTRIES RETINOIDS MARKET, BY THERAPEUTIC CLASS

11.5.6.4.1.2. REMAINING COUNTRIES ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS

11.5.6.4.1.3. REMAINING COUNTRIES OTHERS MARKET, BY THERAPEUTIC CLASS

11.5.6.4.2. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY FORMULATION

11.5.6.4.3. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY TYPE

11.5.6.4.4. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY ACNE TYPE

11.5.6.4.5. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

12. COMPANY PROFILES

12.1. PROCTER & GAMBLE

12.1.1 COMPANY OVERVIEW

12.1.2 COMPANY SNAPSHOT

12.1.3 OPERATING BUSINESS SEGMENTS

12.1.4 PRODUCT PORTFOLIO

12.1.5 BUSINESS PERFORMANCE

12.1.6 SALES BY BUSINESS SEGMENT

12.1.7 SALES BY GEOGRAPHIC SEGMENT

12.1.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.1.9 PRIMARY MARKET COMPETITORS

12.2. UNILEVER PLC

12.2.1 COMPANY OVERVIEW

12.2.2 COMPANY SNAPSHOT

12.2.3 OPERATING BUSINESS SEGMENTS

12.2.4 PRODUCT PORTFOLIO

12.2.5 BUSINESS PERFORMANCE

12.2.6 SALES BY BUSINESS SEGMENT

12.2.7 SALES BY GEOGRAPHIC SEGMENT

12.2.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.2.9 PRIMARY MARKET COMPETITORS

12.3. OBAGI MEDICAL

12.3.1 COMPANY OVERVIEW

12.3.2 COMPANY SNAPSHOT

12.3.3 PRODUCT PORTFOLIO

12.3.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.3.5 PRIMARY MARKET COMPETITORS

12.4. AVON PRODUCTS, INC.

12.4.1 COMPANY OVERVIEW

12.4.2 COMPANY SNAPSHOT

12.4.3 PRODUCT PORTFOLIO

12.4.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.4.5 PRIMARY MARKET COMPETITORS

12.5. HERBALIFE NUTRITION

12.5.1 COMPANY OVERVIEW

12.5.2 COMPANY SNAPSHOT

12.5.3 PRODUCT PORTFOLIO

12.5.4 BUSINESS PERFORMANCE

12.5.5 SALES BY GEOGRAPHIC SEGMENT

12.5.6 KEY STRATEGIC MOVES & DEVELOPMENTS

12.5.7 PRIMARY MARKET COMPETITORS

12.6. BEIERSDORF AG

12.6.1 COMPANY OVERVIEW

12.6.2 COMPANY SNAPSHOT

12.6.3 OPERATING BUSINESS SEGMENTS

12.6.4 PRODUCT PORTFOLIO

12.6.5 BUSINESS PERFORMANCE

12.6.6 SALES BY BUSINESS SEGMENT

12.6.7 SALES BY GEOGRAPHIC SEGMENT

12.6.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.6.9 PRIMARY MARKET COMPETITORS

12.7. ABBVIE INC

12.7.1 COMPANY OVERVIEW

12.7.2 COMPANY SNAPSHOT

12.7.3 OPERATING BUSINESS SEGMENTS

12.7.4 PRODUCT PORTFOLIO

12.7.5 BUSINESS PERFORMANCE

12.7.6 SALES BY BUSINESS SEGMENT

12.7.7 SALES BY GEOGRAPHIC SEGMENT

12.7.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.7.9 PRIMARY MARKET COMPETITORS

12.8. GALDERMA

12.8.1 COMPANY OVERVIEW

12.8.2 COMPANY SNAPSHOT

12.8.3 PRODUCT PORTFOLIO

12.8.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.8.5 PRIMARY MARKET COMPETITORS

12.9. ESTEE LAUDER INC.

12.9.1 COMPANY OVERVIEW

12.9.2 COMPANY SNAPSHOT

12.9.3 OPERATING BUSINESS SEGMENTS

12.9.4 PRODUCT PORTFOLIO

12.9.5 BUSINESS PERFORMANCE

12.9.6 SALES BY BUSINESS SEGMENT

12.9.7 SALES BY GEOGRAPHIC SEGMENT

12.9.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.9.9 PRIMARY MARKET COMPETITORS

12.10. GLAXOSMITHKLINE PLC

12.10.1 COMPANY OVERVIEW

12.10.2 COMPANY SNAPSHOT

12.10.3 OPERATING BUSINESS SEGMENTS

12.10.4 PRODUCT PORTFOLIO

12.10.5 BUSINESS PERFORMANCE

12.10.6 SALES BY BUSINESS SEGMENT

12.10.7 SALES BY GEOGRAPHIC SEGMENT

12.10.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.10.9 PRIMARY MARKET COMPETITORS

12.11. JOHNSON & JOHNSON

12.11.1 COMPANY OVERVIEW

12.11.2 COMPANY SNAPSHOT

12.11.3 OPERATING BUSINESS SEGMENTS

12.11.4 PRODUCT PORTFOLIO

12.11.5 BUSINESS PERFORMANCE

12.11.6 SALES BY BUSINESS SEGMENT

12.11.7 SALES BY GEOGRAPHIC SEGMENT

12.11.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.11.9 PRIMARY MARKET COMPETITORS

12.12. NEUTROGENA

12.12.1 COMPANY OVERVIEW

12.12.2 COMPANY SNAPSHOT

12.12.3 PRODUCT PORTFOLIO

12.12.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.12.5 PRIMARY MARKET COMPETITORS

12.13. HIMALAYA WELLNESS COMPANY

12.13.1 COMPANY OVERVIEW

12.13.2 COMPANY SNAPSHOT

12.13.3 PRODUCT PORTFOLIO

12.13.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.13.5 PRIMARY MARKET COMPETITORS

12.14. ALMIRALL S.A.

12.14.1 COMPANY OVERVIEW

12.14.2 COMPANY SNAPSHOT

12.14.3 OPERATING BUSINESS SEGMENTS

12.14.4 PRODUCT PORTFOLIO

12.14.5 BUSINESS PERFORMANCE

12.14.6 SALES BY GEOGRAPHIC SEGMENT

12.14.7 SALES BY GEOGRAPHIC SEGMENT

12.14.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.14.9 PRIMARY MARKET COMPETITORS

12.15. BAUSCH HEALTH COMPANIES INC.

12.15.1 COMPANY OVERVIEW

12.15.2 COMPANY SNAPSHOT

12.15.3 OPERATING BUSINESS SEGMENTS

12.15.4 PRODUCT PORTFOLIO

12.15.5 BUSINESS PERFORMANCE

12.15.6 SALES BY BUSINESS SEGMENT

12.15.7 SALES BY GEOGRAPHIC SEGMENT

12.15.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.15.9 PRIMARY MARKET COMPETITORS

12.16. AMWAY CORP.

12.16.1 COMPANY OVERVIEW

12.16.2 COMPANY SNAPSHOT

12.16.3 RODUCT PORTFOLIO

12.16.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.16.5 PRIMARY MARKET COMPETITORS

12.17. ABBOTT LABORATORIES

12.17.1 COMPANY OVERVIEW

12.17.2 COMPANY SNAPSHOT

12.17.3 OPERATING BUSINESS SEGMENTS

12.17.4 PRODUCT PORTFOLIO

12.17.5 BUSINESS PERFORMANCE

12.17.6 SALES BY BUSINESS SEGMENT

12.17.7 SALES BY GEOGRAPHIC SEGMENT

12.17.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.17.9 PRIMARY MARKET COMPETITORS

12.18. TEVA PHARMACEUTICALS

12.18.1 COMPANY OVERVIEW

12.18.2 COMPANY SNAPSHOT

12.18.3 PRODUCT PORTFOLIO

12.18.4 BUSINESS PERFORMANCE

12.18.5 SALES BY GEOGRAPHIC SEGMENT

12.18.6 KEY STRATEGIC MOVES & DEVELOPMENTS

12.18.7 PRIMARY MARKET COMPETITORS

12.19. SUN PHARMA

12.19.1 COMPANY OVERVIEW

12.19.2 COMPANY SNAPSHOT

12.19.3 PRODUCT PORTFOLIO

12.19.4 BUSINESS PERFORMANCE

12.19.5 SALES BY GEOGRAPHIC SEGMENT

12.19.6 KEY STRATEGIC MOVES & DEVELOPMENTS

12.19.7 PRIMARY MARKET COMPETITORS

12.20. GLENMARK PHARMACEUTICALS

12.20.1 COMPANY OVERVIEW

12.20.2 COMPANY SNAPSHOT

12.20.3 PRODUCT PORTFOLIO

12.20.4 BUSINESS PERFORMANCE

12.20.5 SALES BY GEOGRAPHIC SEGMENT

12.20.6 KEY STRATEGIC MOVES & DEVELOPMENTS

12.20.7 PRIMARY MARKET COMPETITORS

12.21. VIATRIS

12.21.1 COMPANY OVERVIEW

12.21.2 COMPANY SNAPSHOT

12.21.3 OPERATING BUSINESS SEGMENTS

12.21.4 PRODUCT PORTFOLIO

12.21.5 BUSINESS PERFORMANCE

12.21.6 SALES BY GEOGRAPHIC SEGMENT

12.21.7 KEY STRATEGIC MOVES & DEVELOPMENTS

12.21.8 PRIMARY MARKET COMPETITORS

12.22. PFIZER INC.

12.22.1 COMPANY SNAPSHOT

12.22.2 COMPANY SNAPSHOT

12.22.3 OPERATING BUSINESS SEGMENTS

12.22.4 PRODUCT PORTFOLIO

12.22.5 BUSINESS PERFORMANCE

12.22.6 SALES BY GEOGRAPHIC SEGMENT

12.22.7 SALES BY GEOGRAPHIC SEGMENT

12.22.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.22.9 PRIMARY MARKET COMPETITORS

12.23. MAYNE PHARMA GROUP LIMITED

12.23.1 COMPANY OVERVIEW

12.23.2 COMPANY SNAPSHOT

12.23.3 OPERATING BUSINESS SEGMENTS

12.23.4 PRODUCT PORTFOLIO

12.23.5 BUSINESS PERFORMANCE

12.23.6 SALES BY BUSINESS SEGMENT

12.23.7 SALES BY GEOGRAPHIC SEGMENT

12.23.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.23.9 PRIMARY MARKET COMPETITORS

12.24. CLINIQUE LABORATORIES

12.24.1 COMPANY OVERVIEW

12.24.2 COMPANY SNAPSHOT

12.24.3 PRODUCT PORTFOLIO

12.24.4 KEY STRATEGIC MOVES & DEVELOPMENTS

12.24.5 PRIMARY MARKET COMPETITORS

12.25. COLGATE-PALMOLIVE COMPANY

12.25.1 COMPANY OVERVIEW

12.25.2 COMPANY SNAPSHOT

12.25.3 OPERATING BUSINESS SEGMENTS

12.25.4 PRODUCT PORTFOLIO

12.25.5 BUSINESS PERFORMANCE

12.25.6 SALES BY BUSINESS SEGMENT

12.25.7 SALES BY GEOGRAPHIC SEGMENT

12.25.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.25.9 PRIMARY MARKET COMPETITORS

12.26. L’OREAL

12.26.1 COMPANY OVERVIEW

12.26.2 COMPANY SNAPSHOT

12.26.3 OPERATING BUSINESS SEGMENTS

12.26.4 PRODUCT PORTFOLIO

12.26.5 BUSINESS PERFORMANCE

12.26.6 SALES BY BUSINESS SEGMENT

12.26.7 SALES BY GEOGRAPHIC SEGMENT

12.26.8 KEY STRATEGIC MOVES & DEVELOPMENTS

12.26.9 PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. GLOBAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 2. GLOBAL RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 3. TOPICAL RETINOID & COMBINATION RETIONOID MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 4. ORAL RETINOID (ISORETINION) MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 5. RETINOIDS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 6. GLOBAL ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 7. TOPICAL ANTIBIOTIC & COMBINATION ANTIBIOTICS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 8. ORAL ANTIBIOTIC MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 9. ANTIBIOTICS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 10. SALICYLIC ACID MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 11. BENZOYL PEROXIDE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 12. GLOBAL OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 13. OTHER TOPICALS (AZELAIC ACID) MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 14. OTHERS OTC MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 15. OTHERS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 16. GLOBAL ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 17. TOPICAL MEDICATIONS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 18. ORAL MEDICATIONS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 19. GLOBAL ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 20. PRESCRIPTION MEDICINES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 21. OVER-THE-COUNTER (OTC )MEDICINES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 22. GLOBAL ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 23. INFLAMMATORY ACNE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 24. NON-INFLAMMATORY ACNE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 25. GLOBAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 26. GROCERY SHOPS MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 27. PHARMACIES & DRUG STORES MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 28. E-COMMERCE MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 29. GLOBAL ACNE MEDICATION MARKET, BY REGION, 2021-2030, MILLION USD

TABLE 30. NORTH AMERICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 31. NORTH AMERICA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 32. NORTH AMERICA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 33. NORTH AMERICA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 34. NORTH AMERICA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 35. NORTH AMERICA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 36. NORTH AMERICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 37. NORTH AMERICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 38. NORTH AMERICA ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 39. U.S. ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 40. U.S. RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 41. U.S. ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 42. U.S. OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 43. U.S. ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 44. U.S. ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 45. U.S. ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 46. U.S. ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 47. CANADA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 48. CANADA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 49. CANADA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 50. CANADA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 51. CANADA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 52. CANADA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 53. CANADA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 54. CANADA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 55. MEXICO ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 56. MEXICO RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 57. MEXICO ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 58. MEXICO OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 59. MEXICO ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 60. MEXICO ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 61. MEXICO ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 62. MEXICO ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 63. EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 64. EUROPE RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 65. EUROPE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 66. EUROPE OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 67. EUROPE ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 68. EUROPE ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 69. EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 70. EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 71. EUROPE ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 72. GERMANY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 73. GERMANY RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 74. GERMANY ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 75. GERMANY OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 76. GERMANY ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 77. GERMANY ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 78. GERMANY ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 79. GERMANY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 80. FRANCE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 81. FRANCE RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 82. FRANCE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 83. FRANCE OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 84. FRANCE ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 85. FRANCE ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 86. FRANCE ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 87. FRANCE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 88. UK ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 89. UK RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 90. UK ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 91. UK OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 92. UK ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 93. UK ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 94. UK ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 95. UK ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 96. ITALY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 97. ITALY RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 98. ITALY ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 99. ITALY OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 100. ITALY ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 101. ITALY ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 102. ITALY ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 103. ITALY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 104. SPAIN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 105. SPAIN RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 106. SPAIN ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 107. SPAIN OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 108. SPAIN ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 109. SPAIN ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 110. SPAIN ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 111. SPAIN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 112. REST OF EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 113. REST OF EUROPE RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 114. REST OF EUROPE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 115. REST OF EUROPE OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 116. REST OF EUROPE ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 117. REST OF EUROPE ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 118. REST OF EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 119. REST OF EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 120. ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 121. ASIA-PACIFIC RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 122. ASIA-PACIFIC ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 123. ASIA-PACIFIC OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 124. ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 125. ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 126. ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 127. ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 128. ASIA-PACIFIC ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 129. JAPAN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 130. JAPAN RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 131. JAPAN ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 132. JAPAN OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 133. JAPAN ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 134. JAPAN ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 135. JAPAN ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 136. JAPAN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 137. CHINA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 138. CHINA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 139. CHINA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 140. CHINA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 141. CHINA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 142. CHINA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 143. CHINA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 144. CHINA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 145. INDIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 146. INDIA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 147. INDIA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 148. INDIA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 149. INDIA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 150. INDIA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 151. INDIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 152. INDIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 153. AUSTRALIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 154. AUSTRALIA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 155. AUSTRALIA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 156. AUSTRALIA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 157. AUSTRALIA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 158. AUSTRALIA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 159. AUSTRALIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 160. AUSTRALIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 161. SOUTH KOREA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 162. SOUTH KOREA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 163. SOUTH KOREA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 164. SOUTH KOREA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 165. SOUTH KOREA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 166. SOUTH KOREA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 167. SOUTH KOREA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 168. SOUTH KOREA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 169. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 170. REST OF ASIA-PACIFIC RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 171. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 172. REST OF ASIA-PACIFIC OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 173. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 174. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 175. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 176. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 177. REST OF WORLD ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 178. REST OF WORLD RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 179. REST OF WORLD ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 180. REST OF WORLD OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 181. REST OF WORLD ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 182. REST OF WORLD ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 183. REST OF WORLD ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 184. REST OF WORLD ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 185. REST OF WORLD ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

TABLE 186. BRAZIL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 187. BRAZIL RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 188. BRAZIL ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 189. BRAZIL OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 190. BRAZIL ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 191. BRAZIL ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 192. BRAZIL ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 193. BRAZIL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 194. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 195. KINGDOM OF SAUDI ARABIA (KSA) RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 196. KINGDOM OF SAUDI ARABIA (KSA) ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 197. KINGDOM OF SAUDI ARABIA (KSA) OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 198. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 199. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 200. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 201. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 202. SOUTH AFRICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 203. SOUTH AFRICA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 204. SOUTH AFRICA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 205. SOUTH AFRICA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 206. SOUTH AFRICA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 207. SOUTH AFRICA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 208. SOUTH AFRICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 209. SOUTH AFRICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 210. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 211. REMAINING COUNTRIES RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 212. REMAINING COUNTRIES ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 213. REMAINING COUNTRIES OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

TABLE 214. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

TABLE 215. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

TABLE 216. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

TABLE 217. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

TABLE 218. PROCTER & GAMBLE: COMPANY SNAPSHOT

TABLE 219. PROCTER & GAMBLE: OPERATING SEGMENTS

TABLE 220. PROCTER & GAMBLE: PRODUCT PORTFOLIO

TABLE 221. PROCTER & GAMBLE: BUSINESS SEGMENT

TABLE 222. PROCTER & GAMBLE: GEOGRAPHIC SEGMENT

TABLE 223. PROCTER & GAMBLE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 224. UNILEVER PLC: COMPANY SNAPSHOT

TABLE 225. UNILEVER PLC: OPERATING SEGMENTS

TABLE 226. UNILEVER PLC: PRODUCT PORTFOLIO

TABLE 227. UNILEVER PLC: BUSINESS SEGMENT

TABLE 228. UNILEVER PLC: GEOGRAPHIC SEGMENT

TABLE 229. UNILEVER PLC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 230. OBAGI MEDICAL: COMPANY SNAPSHOT

TABLE 231. OBAGI MEDICAL: PRODUCT PORTFOLIO

TABLE 232. OBAGI MEDICAL: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 233. AVON PRODUCTS, INC.: COMPANY SNAPSHOT

TABLE 234. AVON PRODUCTS, INC: PRODUCT PORTFOLIO

TABLE 235. AVON PRODUCTS, INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 236. HERBALIFE NUTRITION: COMPANY SNAPSHOT

TABLE 237. HERBALIFE NUTRITION: PRODUCT PORTFOLIO

TABLE 238. HERBALIFE NUTRITION: GEOGRAPHIC SEGMENT

TABLE 239. HERBALIFE NUTRITION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 240. BEIERSDORF AG: COMPANY SNAPSHOT

TABLE 241. BEIERSDORF AG: OPERATING SEGMENTS

TABLE 242. BEIERSDORF AG: PRODUCT PORTFOLIO

TABLE 243. BEIERSDORF AG: BUSINESS SEGMENT

TABLE 244. BEIERSDORF AG: GEOGRAPHIC SEGMENT

TABLE 245. BEIERSDORF AG: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 246. ABBVIE INC: COMPANY SNAPSHOT

TABLE 247. ABBVIE INC: OPERATING SEGMENTS

TABLE 248. ABBVIE INC: PRODUCT PORTFOLIO

TABLE 249. ABBVIE INC: NET SALES, 2019–2021 ($MILLION)

TABLE 250. ABBVIE INC: BUSINESS SEGMENT

TABLE 251. ABBVIE INC: GEOGRAPHIC SEGMENT

TABLE 252. ABBVIE INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 253. GALDERMA: COMPANY SNAPSHOT

TABLE 254. GALDERMA.: PRODUCT PORTFOLIO

TABLE 255. GALDERMA.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 256. ESTEE LAUDER INC.: COMPANY SNAPSHOT

TABLE 257. ESTEE LAUDER INC.: OPERATING SEGMENTS

TABLE 258. ESTEE LAUDER INC.: PRODUCT PORTFOLIO

TABLE 259. ESTEE LAUDER INC.: BUSINESS SEGMENT

TABLE 260. ESTEE LAUDER INC.: GEOGRAPHIC SEGMENT

TABLE 261. ESTEE LAUDER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 262. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 263. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 264. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 265. GLAXOSMITHKLINE PLC: BUSINESS SEGMENT

TABLE 266. GLAXOSMITHKLINE PLC: GEOGRAPHIC SEGMENT

TABLE 267. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES & DEVELOPMENT

TABLE 268. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 269. JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 270. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 271. JOHNSON & JOHNSON: BUSINESS SEGMENT

TABLE 272. JOHNSON & JOHNSON: GEOGRAPHIC SEGMENT

TABLE 273. JOHNSON & JOHNSON: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 274. NEUTROGENA: COMPANY SNAPSHOT

TABLE 275. NEUTROGENA: PRODUCT PORTFOLIO

TABLE 276. NEUTROGENA: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 277. HIMALAYA WELLNESS COMPANY: COMPANY SNAPSHOT

TABLE 278. HIMALAYA WELLNESS COMPANY: PRODUCT PORTFOLIO

TABLE 279. HIMALAYA WELLNESS COMPANY: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 280. ALMIRALL S.A.: COMPANY SNAPSHOT

TABLE 281. ALMIRALL S.A.: OPERATING SEGMENTS

TABLE 282. ALMIRALL S.A.: PRODUCT PORTFOLIO

TABLE 283. ALMIRALL S.A.: BUSINESS SEGMENT

TABLE 284. ALMIRALL S.A.: GEOGRAPHIC SEGMENT

TABLE 285. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 286. BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS

TABLE 287. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 288. BAUSCH HEALTH COMPANIES INC.: BUSINESS SEGMENT

TABLE 289. BAUSCH HEALTH COMPANIES INC.: GEOGRAPHIC SEGMENT

TABLE 290. BAUSCH HEALTH COMPANIES INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 291. AMWAY CORP.: COMPANY SNAPSHOT

TABLE 292. AMWAY CORP.: PRODUCT PORTFOLIO

TABLE 293. AMWAY CORP.: KEY STRATEGIC MOVES & DEVELOPMENT

TABLE 294. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 295. ABBOTT LABORATORIES: BUSINESS SEGMENTS

TABLE 296. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 297. ABBOTT LABORATORIES: BUSINESS SEGMENT

TABLE 298. ABBOTT LABORATORIES: GEOGRAPHIC SEGMENT

TABLE 299. ABBOTT LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENT

TABLE 300. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 301. TEVA PHARMACEUTICAL: PRODUCT PORTFOLIO

TABLE 302. TEVA PHARMACEUTICAL: GEOGRAPHIC SEGMENT

TABLE 303. TEVA PHARMACEUTICALS: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 304. SUN PHARMA: COMPANY SNAPSHOT

TABLE 305. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 306. SUN PHARMA: GEOGRAPHIC SEGMENT

TABLE 307. SUN PHARMA: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 308. GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 309. GLENMARK PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 310. GLENMARK PHARMACEUTICALS: GEOGRAPHIC SEGMENT

TABLE 311. GLENMARK PHARMACEUTICALS: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 312. VIATRIS: COMPANY SNAPSHOT

TABLE 313. VIATRIS: OPERATING SEGMENTS

TABLE 314. VIATRIS: PRODUCT PORTFOLIO

TABLE 315. VIATRIS: GEOGRAPHIC SEGMENT

TABLE 316. PFIZER INC.: COMPANY SNAPSHOT

TABLE 317. PFIZER INC.: OPERATING SEGMENTS

TABLE 318. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 319. PFIZER INC.: BUSINESS SEGMENT

TABLE 320. PFIZER INC.: GEOGRAPHIC SEGMENT

TABLE 321. MAYNE PHARMA GROUP LIMITED: COMPANY SNAPSHOT

TABLE 322. MAYNE PHARMA GROUP LIMITED: OPERATING SEGMENTS

TABLE 323. MAYNE PHARMA GROUP LIMITED: PRODUCT PORTFOLIO

TABLE 324. MAYNE PHARMA GROUP LIMITED: BUSINESS SEGMENT

TABLE 325. MAYNE PHARMA GROUP LIMITED: GEOGRAPHIC SEGMENT

TABLE 326. MAYNE PHARMA GROUP LIMITED: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 327. CLINIQUE LABORATORIES: COMPANY SNAPSHOT

TABLE 328. CLINIQUE LABORATORIES: PRODUCT PORTFOLIO

TABLE 329. CLINIQUE LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 330. COLGATE-PALMOLIVE: COMPANY SNAPSHOT

TABLE 331. COLGATE-PALMOLIVE: OPERATING SEGMENTS

TABLE 332. COLGATE-PALMOLIVE: PRODUCT PORTFOLIO

TABLE 333. COLGATE-PALMOLIVE: BUSINESS SEGMENT

TABLE 334. COLGATE-PALMOLIVE: GEOGRAPHIC SEGMENT

TABLE 335. COLGATE-PALMOLIVE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 336. L’OREAL: COMPANY SNAPSHOT

TABLE 337. L’OREAL: OPERATING SEGMENTS

TABLE 338. L’OREAL: PRODUCT PORTFOLIO

TABLE 339. L’OREAL: BUSINESS SEGMENT

TABLE 340. L’OREAL: GEOGRAPHIC SEGMENT

TABLE 341. L’OREAL: KEY STRATEGIC MOVES & DEVELOPMENTS

LIST OF FIGURES

FIGURE 1. MARKET SHARE ANALYSIS OF TOP ACNE MEDICATION PROVIDERS, 2022

FIGURE 2. GLOBAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 3. GLOBAL RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 4. TOPICAL RETINOID & COMBINATION RETIONOID MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 5. ORAL RETINOID (ISORETINION) MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 6. RETINOIDS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 7. GLOBAL ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 8. TOPICAL ANTIBIOTIC & COMBINATION ANTIBIOTICS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 9. ORAL ANTIBIOTIC MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 10. ANTIBIOTICS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 11. SALICYLIC ACID MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 12. BENZOYL PEROXIDE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 13. GLOBAL OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 14. OTHER TOPICALS (AZELAIC ACID) MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 15. OTHERS OTC MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 16. OTHERS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 17. GLOBAL ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 18. TOPICAL MEDICATIONS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 19. ORAL MEDICATIONS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 20. GLOBAL ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 21. PRESCRIPTION MEDICINES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 22. OVER-THE-COUNTER (OTC )MEDICINES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 23. GLOBAL ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 24. INFLAMMATORY ACNE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 25. NON-INFLAMMATORY ACNE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 26. GLOBAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 27. GROCERY SHOPS MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 28. PHARMACIES & DRUG STORES MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 29. E-COMMERCE MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 30. GLOBAL ACNE MEDICATION MARKET, BY REGION, 2021-2030, MILLION USD

FIGURE 31. NORTH AMERICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 32. NORTH AMERICA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 33. NORTH AMERICA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 34. NORTH AMERICA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 35. NORTH AMERICA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 36. NORTH AMERICA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 37. NORTH AMERICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 38. NORTH AMERICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 39. NORTH AMERICA ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 40. U.S. ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 41. U.S. RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 42. U.S. ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 43. U.S. OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 44. U.S. ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 45. U.S. ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 46. U.S. ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 47. U.S. ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 48. CANADA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 49. CANADA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 50. CANADA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 51. CANADA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 52. CANADA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 53. CANADA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 54. CANADA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 55. CANADA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 56. MEXICO ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 57. MEXICO RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 58. MEXICO ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 59. MEXICO OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 60. MEXICO ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 61. MEXICO ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 62. MEXICO ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 63. MEXICO ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 64. EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 65. EUROPE RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 66. EUROPE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 67. EUROPE OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 68. EUROPE ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 69. EUROPE ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 70. EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 71. EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 72. EUROPE ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 73. GERMANY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 74. GERMANY RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 75. GERMANY ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 76. GERMANY OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 77. GERMANY ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 78. GERMANY ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 79. GERMANY ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 80. GERMANY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 81. FRANCE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 82. FRANCE RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 83. FRANCE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 84. FRANCE OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 85. FRANCE ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 86. FRANCE ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 87. FRANCE ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 88. FRANCE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 89. UK ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 90. UK RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 91. UK ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 92. UK OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 93. UK ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 94. UK ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 95. UK ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 96. UK ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 97. ITALY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 98. ITALY RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 99. ITALY ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 100. ITALY OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 101. ITALY ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 102. ITALY ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 103. ITALY ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 104. ITALY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 105. SPAIN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 106. SPAIN RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 107. SPAIN ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 108. SPAIN OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 109. SPAIN ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 110. SPAIN ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 111. SPAIN ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 112. SPAIN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 113. REST OF EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 114. REST OF EUROPE RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 115. REST OF EUROPE ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 116. REST OF EUROPE OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 117. REST OF EUROPE ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 118. REST OF EUROPE ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 119. REST OF EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 120. REST OF EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 121. ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 122. ASIA-PACIFIC RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 123. ASIA-PACIFIC ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 124. ASIA-PACIFIC OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 125. ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 126. ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 127. ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 128. ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 129. ASIA-PACIFIC ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 130. JAPAN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 131. JAPAN RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 132. JAPAN ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 133. JAPAN OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 134. JAPAN ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 135. JAPAN ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 136. JAPAN ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 137. JAPAN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 138. CHINA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 139. CHINA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 140. CHINA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 141. CHINA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 142. CHINA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 143. CHINA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 144. CHINA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 145. CHINA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 146. INDIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 147. INDIA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 148. INDIA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 149. INDIA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 150. INDIA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 151. INDIA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 152. INDIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 153. INDIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 154. AUSTRALIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 155. AUSTRALIA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 156. AUSTRALIA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 157. AUSTRALIA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 158. AUSTRALIA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 159. AUSTRALIA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 160. AUSTRALIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 161. AUSTRALIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 162. SOUTH KOREA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 163. SOUTH KOREA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 164. SOUTH KOREA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 165. SOUTH KOREA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 166. SOUTH KOREA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 167. SOUTH KOREA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 168. SOUTH KOREA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 169. SOUTH KOREA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 170. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 171. REST OF ASIA-PACIFIC RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 172. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 173. REST OF ASIA-PACIFIC OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 174. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 175. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 176. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 177. REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 178. REST OF WORLD ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 179. REST OF WORLD RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 180. REST OF WORLD ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 181. REST OF WORLD OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 182. REST OF WORLD ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 183. REST OF WORLD ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 184. REST OF WORLD ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 185. REST OF WORLD ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 186. REST OF WORLD ACNE MEDICATION MARKET, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 187. BRAZIL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 188. BRAZIL RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 189. BRAZIL ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 190. BRAZIL OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 191. BRAZIL ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 192. BRAZIL ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 193. BRAZIL ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 194. BRAZIL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 195. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 196. KINGDOM OF SAUDI ARABIA (KSA) RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 197. KINGDOM OF SAUDI ARABIA (KSA) ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 198. KINGDOM OF SAUDI ARABIA (KSA) OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 199. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 200. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 201. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 202. KINGDOM OF SAUDI ARABIA (KSA) ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 203. SOUTH AFRICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 204. SOUTH AFRICA RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 205. SOUTH AFRICA ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 206. SOUTH AFRICA OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 207. SOUTH AFRICA ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 208. SOUTH AFRICA ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 209. SOUTH AFRICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 210. SOUTH AFRICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 211. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 212. REMAINING COUNTRIES RETINOIDS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 213. REMAINING COUNTRIES ANTIBIOTICS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 214. REMAINING COUNTRIES OTHERS MARKET, BY THERAPEUTIC CLASS, 2021-2030, MILLION USD

FIGURE 215. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY FORMULATION, 2021-2030, MILLION USD

FIGURE 216. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY TYPE, 2021-2030, MILLION USD

FIGURE 217. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY ACNE TYPE, 2021-2030, MILLION USD

FIGURE 218. REMAINING COUNTRIES ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2021-2030, MILLION USD

FIGURE 219. PROCTER & GAMBLE: NET SALES, 2019–2021 ($MILLION)

FIGURE 220. PROCTER & GAMBLE: PRIMARY MARKET COMPETITORS

FIGURE 221. UNILEVER PLC: NET SALES, 2019–2021 ($MILLION)

FIGURE 222. UNILEVER PLC: PRIMARY MARKET COMPETITORS

FIGURE 223. OBAGI MEDICAL: PRIMARY MARKET COMPETITORS

FIGURE 224. AVON PRODUCTS, INC: PRIMARY MARKET COMPETITORS

FIGURE 225. HERBALIFE NUTRITION: NET SALES, 2019–2021 ($MILLION)

FIGURE 226. HERBALIFE NUTRITION: PRIMARY MARKET COMPETITORS

FIGURE 227. BEIERSDORF AG: NET SALES, 2019–2021 ($MILLION)

FIGURE 228. BEIERSDORF AG: PRIMARY MARKET COMPETITORS

FIGURE 229. ABBVIE INC.: PRIMARY MARKET COMPETITORS

FIGURE 230. GALDERMA.: PRIMARY MARKET COMPETITORS

FIGURE 231. ESTEE LAUDER INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 232. ESTEE LAUDER INC.: PRIMARY MARKET COMPETITORS

FIGURE 233. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($ MILLION)

FIGURE 234. GLAXOSMITHKLINE PLC: PRIMARY MARKET COMPETITORS

FIGURE 235. JOHNSON & JOHNSON, 2019–2021 ($MILLION)

FIGURE 236. JOHNSON & JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 237. NEUTROGENA: PRIMARY MARKET COMPETITORS

FIGURE 238. HIMALAYA WELLNESS COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 239. ALMIRALL S.A.: NET SALES, 2019–2021 (USD MILLION)

FIGURE 240. ALMIRALL S.A.: PRIMARY MARKET COMPETITORS

FIGURE 241. BAUSCH HEALTH COMPANIES INC.: NET SALES, 2019–2021 (USD MILLION)

FIGURE 242. BAUSCH HEALTH COMPANIES INC.: PRIMARY MARKET COMPETITORS

FIGURE 243. AMWAY CORP: PRIMARY MARKET COMPETITORS

FIGURE 244. ABBOTT LABORATORIES: NET SALES, 2019–2021 ($ MILLION)

FIGURE 245. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 246. TEVA PHARMACEUTICALS: NET SALES, 2019–2021 ($ MILLION)

FIGURE 247. TEVA PHARMACEUTICALS: PRIMARY MARKET COMPETITORS

FIGURE 248. SUN PHARMA: NET SALES, 2019–2021 ($MILLION)

FIGURE 249. SUN PHARMA: PRIMARY MARKET COMPETITORS

FIGURE 250. GLENMARK PHARMACEUTICALS, 2019–2021 ($MILLION)

FIGURE 251. GLENMARK PHARMACEUTICALS: PRIMARY MARKET COMPETITORS

FIGURE 252. VIATRIS: NET SALES, 2019–2021 ($MILLION)

FIGURE 253. VIATRIS: PRIMARY MARKET COMPETITORS

FIGURE 254. PFIZER INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 255. PFIZER INC.: PRIMARY MARKET COMPETITORS

FIGURE 256. MAYNE PHARMA GROUP LIMITED: NET SALES, 2019–2021 ($MILLION)

FIGURE 257. MAYNE PHARMA GROUP LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 258. CLINIQUE LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 259. COLGATE-PALMOLIVE: NET SALES, 2019–2021 ($MILLION)

FIGURE 260. COLGATE-PALMOLIVE: PRIMARY MARKET COMPETITORS

FIGURE 261. L’OREAL: NET SALES, 2019–2021 ($MILLION)

FIGURE 262. L’OREAL: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

Benzoyl peroxide, retinol, and salicylic acid-based products treat acne quickly.

Wash your face daily, know your skin type, use moisturizers, stay hydrated, and limit sun exposure.

Blackheads, whiteheads, papules, and pustules.

Vitamin A, D, zinc, and E.

One can add salmon, anchovies, sardines, and mackerel in their diet to treat acne scars. These are rich in antioxidants, which help to reduce inflammation.

Download Free Sample

Phone Number *

Please enter Country Code and Phone No

Yes, I have read the Privacy Policy

Multi User

$4,975

Single User

$3,975

Enterprise

$6,975

Datapack

$2,975

Our Clients

View All

Features
	Single User	Multi User	Enterprise User	Data Pack
	US $ 3,975	US $ 4,975	US $ 6,975	US $ 2,975
	1 user only	1 user only	Unlimited access within the Organization	1 user only

Free Customization	20 hours	40 hours	>60 hours	NA
Duration Of Free Analyst Support	3 months post purchase	6 months post purchase	12 months post purchase	NA
Direct Access to the Analyst Team Through Calls / Email
Deliverable Format
Deliverable Format
Discount on Your Next Purchase	No Discount	15%	No Discount	No Discount
Permission to Print the Report

Trending Report

Acne Medication Market

Market Definition

Adoption of Acne Medication, Owing to Unhealthy Food Habits and Sedentary Lifestyles

Occurrence of Acne Vulgaris Condition in Teenagers and Adults

Side Effects of Acne Medications and Substitute Acne Treatment Options

The Emergence of Effective Acne Medications with Minor Side Effects

North America Holds a Major Share of the Acne Drug Market

Europe is Expected to Show a Steady Rise in the Acne Medication Market

Competitive Landscape

Acne Medication Market Key Segments

By Therapeutic Class

By Formulation

By Type

By Acne Type

By Distribution Channel

By Region

Report Scope and Segmentation

KEY PLAYERS

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

Frequently Asked Questions

Download Free Sample

Our Clients

Features

Follow Us On

We Accept

Industries

Trending Report

Acne Medication Market

Market Definition

Adoption of Acne Medication, Owing to Unhealthy Food Habits and Sedentary Lifestyles

Occurrence of Acne Vulgaris Condition in Teenagers and Adults

Side Effects of Acne Medications and Substitute Acne Treatment Options

The Emergence of Effective Acne Medications with Minor Side Effects

North America Holds a Major Share of the Acne Drug Market

Europe is Expected to Show a Steady Rise in the Acne Medication Market

Competitive Landscape

Acne Medication Market Key Segments

By Therapeutic Class

By Formulation

By Type

By Acne Type

By Distribution Channel

By Region

Report Scope and Segmentation

KEY PLAYERS

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

Frequently Asked Questions

Which is the best medicine to treat acne?

How could we avoid acne?

What are the types of acne?

What are the best vitamins used for clear skin?

What is the best diet to treat acne scars?

Download Free Sample

Our Clients

Related Report

Related Blogs

Breaking New Ground In Acne Treatment: Spotlight On The Top 5 Players

Why Avolta (DUFRY) and Lagardere are the Powerhouses of the Travel Retail Sector – Insights you need to know

Stay Ahead with the Top Skincare Trends of 2023!